Ionis Pharmaceuticals (LTS:0JDI) Price-to-Tangible-Book : 16.21 (As of May. 03, 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-03), Ionis Pharmaceuticals's share price is $43.43. Ionis Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $2.68. Hence, Ionis Pharmaceuticals's Price to Tangible Book Ratio of today is 16.21.

The historical rank and industry rank for Ionis Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

LTS:0JDI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.79 Med: 14.99 Max: 73.47
Current: 16.09

During the past 13 years, Ionis Pharmaceuticals's highest Price to Tangible Book Ratio was 73.47. The lowest was 5.79. And the median was 14.99.

LTS:0JDI's Price-to-Tangible-Book is ranked worse than
93.78% of 1222 companies
in the Biotechnology industry
Industry Median: 2.75 vs LTS:0JDI: 16.09

A closely related ratio is called PB Ratio. As of today, Ionis Pharmaceuticals's share price is $43.43. Ionis Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.68. Hence, Ionis Pharmaceuticals's P/B Ratio of today is 16.21.

Ionis Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Ionis Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Price-to-Tangible-Book Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

5.97

11.43

7.15

9.33

14.05

Ionis Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															9.33	11.06	12.58	17.10	14.05

Competitive Comparison of Ionis Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Ionis Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ionis Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Price-to-Tangible-Book falls into.

Ionis Pharmaceuticals Price-to-Tangible-Book Calculation

Ionis Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	43.43	/	2.679
	=	16.21

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Ionis Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (LTS:0JDI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (LTS:0JDI) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

IONS:USA IONS:Mexico ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (LTS:0JDI) Headlines

No Headlines